Search

Researchers at Michigan State University conducted a study on prescription pain reliever misuse among transgender and gender diverse adults. The study found that certain sociodemographic factors such as gender identity, race/ethnicity, and sexual orientation influenced the likelihood of PPR misuse among TGD individuals. Additionally, individuals who had been diagnosed with anxiety or experienced discrimination in mental health care settings were more likely to misuse PPRs. The research emphasizes the importance of considering the impact of multiple marginalized identities within the TGD community when addressing non-PPR misuse. [Extracted from the article]

A patent has been issued to Nippon Chemiphar Co. Ltd. for the use of morphinan derivatives in treating opioid delta receptor agonist-related diseases, such as headaches. The patent, filed in December 2022 and published in October 2024, outlines the pharmaceutical composition and compounds involved in the treatment. The inventors aim to provide a medicament for therapeutic or prophylactic treatment of opioid delta receptor-related diseases, focusing on pain-associated anxiety or depression in mammalian subjects. [Extracted from the article]

Researchers at Urmia University of Medical Sciences in Iran conducted a study on the use of Curcumin-loaded nanofibers for extended analgesia after laminectomy in rats. The nanofibers were designed to release Curcumin over a period of 5 weeks, resulting in decreased pain scores and enhanced pain relief in the rats. The findings suggest that these nanofibers could provide controlled release of Curcumin for prolonged pain management after surgery. [Extracted from the article]

A recent study conducted by the Department of Chemistry in Haryana, India, explores the therapeutic potential of pyrazole-thiazole hybrids in the field of analgesics. These hybrids have shown a wide range of pharmacological activities, including anticancer, antifungal, antibacterial, analgesic, anti-inflammatory, antioxidant, and more. The research aims to provide insights into the structure-activity relationships and mechanisms of action of these compounds, offering a platform for the development of more effective and targeted medications. This peer-reviewed study offers a comprehensive review of the biological profile of pyrazole-thiazole hybrids, highlighting their potential in various therapeutic applications. [Extracted from the article]

The article discusses a new approach to optimizing analgesic and sedative therapy in critically ill adults through pharmacogenomics at New York Presbyterian Hospital. The research emphasizes the importance of tailoring medication based on an individual's genetic makeup and other factors to maximize effectiveness and safety. The study aims to improve clinical outcomes and reduce safety concerns by utilizing a precision medicine approach in intensive care unit patients. [Extracted from the article]

A recent report from Alma Mater Studiorum - University of Bologna discusses the use of opioids in managing chronic pain, a condition that affects approximately 30% of the population. While opioids are commonly used to treat moderate-to-severe pain in both cancer and non-cancer patients, their chronic use can lead to various side effects. The report highlights the importance of understanding the molecular mechanisms behind the analgesic effects and adverse events of opioids to improve chronic pain treatment. For more information, the full article can be accessed for free at https://doi.org/10.1186/s44158-024-00201-2. [Extracted from the article]

A recent study from the University of Sao Paulo explores the potential of targeting protein-protein interactions (PPIs) to develop new analgesics for chronic pain. By focusing on specific interactions involved in pain signaling pathways, researchers aim to create more selective drugs with fewer side effects. This approach could improve the clinical management of pain by providing new avenues for drug development. The study was published in Science Signaling and can be accessed for free online. [Extracted from the article]

Researchers at Sichuan University in Chengdu, China, have developed a new long-acting analgesic formulation for postoperative pain management. The formulation, which combines levobupivacaine hydrochloride and meloxicam in vesicular phospholipid gels, showed extended release duration of up to 120 hours and optimal postoperative analgesia in in vivo studies. This promising development aims to provide effective and long-lasting pain relief, potentially reducing the need for opioids and hospitalization duration. [Extracted from the article]

A recent study conducted at the University of Manchester examined the use of over-the-counter supplements, sleep aids, and analgesic medicines in patients with Rheumatic and Musculoskeletal diseases (RMDs). The research found that a significant number of patients reported daily supplement intake, with common supplements including vitamin D, multivitamins, and Omega 3/6 supplements. Additionally, a high percentage of respondents reported using prescription, over-the-counter, or non-prescription pain relief, with some patients also using sleep aids. The study concluded that healthcare professionals should proactively inquire about these practices during consultations to provide appropriate advice and ensure patient safety. [Extracted from the article]

Researchers at the University of Balikesir conducted a case study on an elderly female patient with persistent headaches and diarrhea, ultimately diagnosed with Immunoglobulin G4 (IgG4)-related disease. Despite initial treatment with analgesics, the patient did not respond until receiving pulse therapy and oral azathioprine, followed by rituximab therapy. This case underscores the importance of considering IgG4-related disease in elderly patients with treatment-resistant headaches, as it can be effectively managed with steroids and monoclonal antibodies. The study was published in Encephalitis and can be accessed for free online. [Extracted from the article]

Researchers from Tehran University of Medical Sciences conducted a randomized controlled trial to evaluate the effects of adding gabapentin to a ketorolac-based regimen for acute renal colic pain. The study found that patients who received gabapentin in addition to the standard treatment showed significantly lower pain severity and reduced need for morphine compared to the control group. This suggests that gabapentin may be a beneficial adjunct to standard analgesic regimens for managing acute renal colic pain. The research highlights the potential of gabapentin to decrease opioid reliance in pain management. [Extracted from the article]

A recent study conducted by researchers at Gonabad University of Medical Sciences examined the potential adverse effects of tramadol exposure on the hippocampus within the central nervous system. The study found that tramadol may lead to neuropsychological impairments, such as memory formation, attention deficits, and cognitive impairment, by impacting neural structures and cellular function within the hippocampus. Further research is needed to fully understand the mechanisms behind these effects. The study highlights the importance of investigating the impacts of tramadol on the central nervous system. [Extracted from the article]

A clinical trial, NCT06632691, aims to study the benefit of medical hypnosis provided by a virtual reality headset in improving the tolerance of lower digestive endoscopy in patients with ulcerative colitis. The ACCEPT study revealed that the acceptability of rectosigmoidoscopy is low due to pain, bloating, and embarrassment during the examination. Virtual reality headsets offer analgesic and anxiolytic properties through specially designed virtual environments, incorporating principles like medical hypnosis and music therapy. The trial, set to conclude in April 2027, will involve 100 participants and is led by the Centre Hospitalier Departemental Vendee in France. [Extracted from the article]

A clinical trial, NCT06627816, is being conducted to compare the efficacy of intravenous nefopam, dexmedetomidine, and meperidine in preventing post-spinal anesthesia shivering in adult patients undergoing lower abdominal and lower limb surgeries. The study aims to evaluate the effectiveness of nefopam while minimizing side effects. Patients administered nefopam experience less sedation and hypotension compared to those given dexmedetomidine, but further research is needed to assess nefopam's effects on preventing shivering after neuraxial blockades. [Extracted from the article]

The patent application titled "Ketorolac Liquid Composition, Preparation Method Therefor, And Application Thereof" discusses the development of a ketorolac liquid composition that aims to address the limitations of existing ketorolac preparations. The composition includes components such as ketorolac, stabilizers, osmolarity regulators, pH regulators, and buffers, with a focus on eliminating ethanol to enhance stability, reduce irritation, and improve safety. This innovation offers a promising solution for manufacturing anti-inflammatory medications with improved efficacy and patient compliance. [Extracted from the article]